VNDA

Vanda Pharmaceuticals Inc

VNDA, USA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

https://www.vandapharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$11.75

Analyst Picks

Strong Buy

1

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.79

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-4.85 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.76 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-56.50 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.29

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 78.63% of the total shares of Vanda Pharmaceuticals Inc

1.

BlackRock Inc

(15.9685%)

since

2025/06/30

2.

Vanguard Group Inc

(6.0465%)

since

2025/06/30

3.

Renaissance Technologies Corp

(5.8343%)

since

2025/06/30

4.

Millennium Management LLC

(5.2807%)

since

2025/06/30

5.

Dimensional Fund Advisors, Inc.

(4.376%)

since

2025/06/30

6.

TANG CAPITAL MANAGEMENT LLC

(3.9826%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(2.8855%)

since

2025/07/31

8.

Geode Capital Management, LLC

(2.8629%)

since

2025/06/30

9.

iShares Russell 2000 ETF

(2.2527%)

since

2025/08/31

10.

State Street Corp

(2.1423%)

since

2025/06/30

11.

BlackRock Advantage Small Cap Core Instl

(1.7482%)

since

2025/07/31

12.

Krensavage Asset Management, LLC

(1.7345%)

since

2025/06/30

13.

Morgan Stanley - Brokerage Accounts

(1.5239%)

since

2025/06/30

14.

Citigroup Inc

(1.4903%)

since

2025/06/30

15.

Connor Clark & Lunn Inv Mgmt Ltd

(1.4697%)

since

2025/06/30

16.

Two Sigma Advisers, LLC

(1.3695%)

since

2025/06/30

17.

Federated Hermes Inc

(1.2329%)

since

2025/06/30

18.

Federated Hermes MDT SCC Institutional

(1.057%)

since

2025/06/30

19.

Federated Hermes MDT Small Cap Core IS

(1.057%)

since

2025/06/30

20.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0427%)

since

2025/07/31

21.

Prudential Financial Inc

(1.0256%)

since

2025/06/30

22.

Fidelity Small Cap Index

(0.9387%)

since

2025/06/30

23.

Two Sigma Investments LLC

(0.8916%)

since

2025/06/30

24.

iShares Russell 2000 Value ETF

(0.8116%)

since

2025/08/31

25.

Marshall Wace Asset Management Ltd

(0.7983%)

since

2025/06/30

26.

Northern Trust Corp

(0.777%)

since

2025/06/30

27.

Charles Schwab Investment Management Inc

(0.7619%)

since

2025/06/30

28.

DFA US Targeted Value I

(0.7526%)

since

2025/07/31

29.

Goldman Sachs Group Inc

(0.6883%)

since

2025/06/30

30.

DFA US Small Cap Value I

(0.6804%)

since

2025/07/31

31.

Dimensional US Targeted Value ETF

(0.6199%)

since

2025/08/29

32.

Profit Inv Mgt (PIM) Profit Sm Cap Eq

(0.5582%)

since

2025/06/30

33.

iShares Biotechnology ETF

(0.5565%)

since

2025/08/31

34.

Acadian Global Small-Cap Equity CIT Cl A

(0.5391%)

since

2025/03/04

35.

Fidelity Extended Market Index

(0.5315%)

since

2025/07/31

36.

Blackrock Russell 2000 Alpha Tilts Fd A

(0.4822%)

since

2025/06/30

37.

Russell 2500 Alpha Tilts Fund T

(0.4814%)

since

2025/06/30

38.

SQUAD Aguja Opportunities I

(0.4739%)

since

2025/05/31

39.

Schwab US Small-Cap ETFâ„¢

(0.4582%)

since

2025/08/30

40.

Vanguard Russell 2000 ETF

(0.4483%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.38

EPS Estimate

-0.45

EPS Difference

0.07

Surprise Percent

15.5556%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.